Date: Tue, 2015-08-18
Hannah Leonie Prinzler gives an amazing interview about her Documentary – The Patent Wars –
Click HERE to read the article.
Date: Mon, 2015-08-17
Listen to Dr. Martin expand on the who, what and how the Future Dreaming Documentary came about.
Date: Mon, 2015-08-10
M·CAM Inc. is an enterprise explicitly committed to the global alignment of innovation and efficient, integral capital. Ask the average person about M·CAM and, if they know about it at all, they will usually describe one facet of the entity that has successfully transformed the world’s view of intangible assets in economic systems. “Make it simple,” is the refrain I hear about the world. Put it in “plain English” please.
Please click HERE to continue reading!
Date: Mon, 2015-08-03
Future Dreaming is a remarkable documentary that will challenge the way you think about humanity. The film explores the narratives that drive our economic, social and political thinking and offers a new way of understanding the Human Condition.
Watch all three Trailers:
Date: Mon, 2015-07-20
Our good friend Russell Okung was published in an Article “Betting on Myself”
“The fact of the matter is that even if the agent-player relationship is a close, heartfelt, personal one, it’s still founded on one thing: money.” – Russell Okung
Read the entire article HERE
Date: Thu, 2015-06-11
Washington, D.C. – The House Judiciary Committee today approved the Innovation Act (H.R. 9) by an overwhelming vote of 24-8. This bipartisan bill takes steps to combat the ever increasing problem of abusive patent litigation. The legislation addresses abusive practices taking place in our courts.
House Judiciary Committee Chairman and chief sponsor of the Innovation Act Bob Goodlatte (R-Va.), praised today’s Committee vote.
Chairman Goodlatte: “At its core, abusive patent litigation is a drag on our economy and stifles innovation. It is a problem that impacts businesses and industries of all types and the jobs of the people who work for them, from the tech sector to the hospitality industry and even grocery stores. Everyone from independent inventors, to start-ups, to mid-and large-sized businesses face this constant threat. The tens of billions of dollars squandered on settlements and litigation expenses associated with abusive patent suits represent truly wasted capital – capital that could have been used to create new jobs, fund research and development, and create new innovations and technologies.
“The Innovation Act takes the necessary steps to address abusive patent litigation, while protecting legitimate property rights. Specifically, the legislation targets abusive behavior rather than specific entities, preserves valid patent enforcement tools, preserves patent property rights, promotes invention by independents and small businesses, and strengthens the overall patent system.”
Key Components of the Innovation Act:
Targets Abusive Patent Litigation: The bill targets abusive patent litigation behavior and not specific entities with the goal of preventing individuals from taking advantage of gaps in the system to engage in litigation extortion. It does not attempt to eliminate valid patent litigation.
Protects the Patent System: This legislation does not diminish or devalue patent rights in any way.
Increases Transparency: This legislation requires greater transparency in patent litigation and requires parties to explain exactly why they are suing a business or individual. Requiring parties to do a bit of due diligence up front before filing an infringement suit is just plain common sense. It not only reduces litigation expenses, but saves the court’s time and resources. Greater transparency and information is a good thing and it makes our patent system stronger.
Prevents Extortion: The legislation prevents any one party in a patent lawsuit from unilaterally racking up extreme litigation costs for another party in an attempt to force a dubious settlement.
Provides Greater Clarity: The legislation provides for more clarity surrounding initial discovery, case management, joinder and the common law doctrine of customer stays. The bill works hand-in-hand with the procedures and practices of the Judicial Conference and the courts.
Small Business Education: The bill provides for small business education and outreach by the U.S. Patent and Trademark Office.
Places Reasonable Limits on Venue in Patent Cases: Restores Congress’s intent that patent infringement suits only be brought in judicial districts that have some reasonable connection to the dispute. Since 1897, Congress has regulated the venue in which patent actions may be brought. These limits protect parties against the burden and inconvenience of litigating patent lawsuits in districts that are remote from any of the underlying events in the case. In 1990 the U.S. Court of Appeals for the Federal Circuit “reinterpreted” that statute in a way that robbed it of all effect. The Innovation Act corrects the Federal Circuit’s error, and restores the congressional purpose of placing some reasonable limits on the venue where a patent action may be brought.
Reduces Unnecessary, Expensive Discovery: Requires that courts stay discovery in a patent case when a motion to dismiss or a motion to transfer has been filed. This will help parties avoid expensive, wasteful discovery that might otherwise be used as leverage by patent trolls looking for a quick settlement when a case can be resolved quickly and early.
VIDEO: Learn more about the importance of protecting and promoting American innovation by curbing abusive patent litigation by clicking HERE
Date: Wed, 2015-06-10
M·CAM releases Patently Obvious® on How Attractive is Chimerix
While Chimerix’s fully owned patent portfolio is fairly small, a number of licensing agreements have allowed the company to develop beyond its own proprietary technology. Combining in-house and licensed patents gives Chimerix a strong exclusivity position if its CMX001 and CMX157 candidates pass through clinical trials. With no glaring prior art problems and strong third-party interest in its technology, the market may be overweighting Chimerix’s IP risk. M·CAM believes the company’s IP risk is lower than industry average, which should allow for a clean product launch and make Chimerix an attractive acquisition target for Gilead, Novartis, and other large pharma players.
M·CAM’s Patently Obvious® is a report providing visibility into potentially unconsidered alternatives, including art in the public domain, to patent holdings across a variety of technology areas.
M·CAM is a global, full-service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.
The M·CAM Patently Obvious® on How Attractive is Chimerix can be found HERE
Date: Wed, 2015-06-10
M·CAM releases Patently Obvious® on Avago Technologies Suing Maxim Integrated Products.
On April 23rd, 2015, Avago Technologies General IP (Singapore) PTE. LTD filed suit against Maxim Integrated Products, Inc. regarding their semiconductor devices. Avago claims that Maxim infringes on five patents (US 5,523,359; US 5,599,739; US 6,040,616; US 6,083,271; and US 6,194,323) when manufacturing its MAX6946, MAX2634, MAX7356, MAX17126, DS28E10, MAX1305, and other semiconductor products. Maxim had, for nearly two decades, licensed semiconductor technologies from LSI Corporation’s patent portfolio. The license to these technologies lapsed on December 31, 2011. Avago acquired LSI in 2014, and claims that Maxim has continued to benefit from the technologies represented by the LSI portfolio. These technologies broadly cover methods for improved integrated circuit fabrication and design, including hard mask etching, barrier layer treatment, and specifying multiple power domains.
M·CAM’s Patently Obvious® is a report providing visibility into potentially unconsidered alternatives, including art in the public domain, to patent holdings across a variety of technology areas.
M·CAM is a global, full-service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.
The M·CAM Patently Obvious® on Avago Technologies Suing Maxim Integrated Products can be found HERE.
FOR IMMEDIATE RELEASE
Celgene’s Revlimid® Patents Do Not Withstand Review
CHARLOTTESVILLE, VA – On May 7, 2015, the European Patent Office revoked one of Celgene’s (NASDAQ: CELG) patents on Revlimid®. Revlimid® reportedly accounts for almost $5 billion of Celgene’s nearly $7.5 billion in annual revenue and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer and other autoimmune diseases.
A systematic and rigorous review of the available precedent information, undertaken by M·CAM, provides a sound basis for the invalidation of many other Revlimid® patents, including those currently listed in the FDA’s Orange Book, on the grounds that they are based on an older drug and that the use of the drug in the treatment of cancer was obvious. If the invalidation of the entire Revlimid® portfolio were systematically pursued by a third party, it could materially and adversely impact Celgene.
Simply put, the core Revlimid® compound patent, U.S. Pat. No. 5,635,517 (‘517), is and has always been based on an old drug (thalidomide) and the “innovations” on which Revlimid is based, going back to its priority date in 1996, are obvious in light of precedent innovation. As a result, the ‘517 patent should not be entitled to patent protection in the United States or any of the nearly 70 countries where Revlimid® is approved. Since this base patent of the Revlimid® families of patents is not valid, then many of the Revlimid® patents are subject to validity or commercial relevance challenges.
The full report can be found at Harvest Exchange.
About M·CAM
M·CAM is a global financial institution that advises corporations and investors on corporate finance and asset allocation by underwriting intellectual property (IP) and intangible assets (IA). From its roots in providing financial products enabling lenders to use IP and IA as regulatory acceptable collateral for lending, M·CAM’s capital solutions address the financial needs of businesses and investors in the Knowledge Economy. M·CAM has been providing capital markets solutions to financial, sovereign, and corporate institutions since its inception in 1998.
contact@m-cam.com
210 Ridge-McIntire Road
Charlottesville, VA 22902
www.m-cam.com
434-979-7240
Date: Tue, 2015-04-21
Mechanics of Consciousness and The Metamoney Artifact RVU April 21, 2015 – May 24, 2015
M·CAM Inc. is pleased to present Mechanics of Consciousness and The Metamoney Artifact RVU, an exhibition by Dylan Korelich. This series of oil paintings explores and continues the dialog between art, religion, science and esoteric symbolism. It is a narrative that employs the aesthetics and techniques of the old masters and the argument of form presented in modern abstract painting. The impulse is to revisit the questions of rationalism and empiricism in the dawn of a world where the artifact maybe reduced to a coded reconstruction in brain computer interface technology (BCI) and augmented reality applications. It questions what does it mean to be conscious? How do we form our values? And is it possible to capture our experience through the lens of an objective observer?
The Metamoney Artifact RVU is working symbol and it’s memory of transaction are a testament to a working model of value exchange using the principles of Integral Accounting. Rather than denominating an impulse to conclude and thereby terminate a relationship between transacting parties, it serves as a token of remembrance of the provision and receipt of value. As it can fulfill this function in any environment for any purpose, the RVU has placed the responsibility of stewardship and remembrance on all parties engaging with it.
To read more about the exhibition, Click HERE
